Xultophy provided superior blood sugar reduction (HbA1c) compared to insulin glargine U-100 in DUAL IX trial. Novo Nordisk.

Xultophy (insulin degludec and liraglutide injection) provided superior blood sugar reduction (HbA1c) compared to insulin glargine U-100 (1.94% vs 1.68% respectively; p<0.0001) when used as an add-on to an SGLT-2i (an oral diabetes medication), according to results from the DUAL IX study presented at the American Diabetes Association's 78th Scientific Sessions (ADA) in Orlando, US. Results from some of the secondary endpoints in DUAL IX included change from baseline in body weight, severe or blood glucose confirmed symptomatic hypoglycaemic events and daily insulin dose at 26 weeks. Mean body weight remained unchanged in the Xultophy study group versus a 2.0 kg weight gain with insulin glargine U-100. Treatment with Xultophy demonstrated a 58% lower rate of hypoglycaemia versus insulin glargine U-100 (0.37 events/patient-year of exposure vs 0.90 events/patient-year of exposure respectively; p=0.0035). The average total daily insulin dose was significantly less with Xultophy than insulin glargine U-100 (36 units per day vs 54 units per day respectively; p<0.0001). Adverse events were similar across both treatment groups; the most common adverse events (>5%) in the Xultophy treated patients included viral upper respiratory tract infection, headaches, back pain, increased lipase and nausea. The safety profile of Xultophy in DUAL IX was consistent with previous Xultophy clinical trials.Additional DUAL IX patient-reported outcomes will be presented on Monday 25 June at ADA: Patient-Reported Outcomes for Insulin Degludec/Liraglutide (IDegLira) vs Insulin Glargine (IGlar U-100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes: DUAL IX Trial (Poster Presentation 101-LB).